Related references
Note: Only part of the references are listed.Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
Andres Felipe Cardona et al.
PLOS ONE (2016)
REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells
Wenjie Wang et al.
ONCOLOGY REPORTS (2015)
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
Cristina Chamizo et al.
BMC PULMONARY MEDICINE (2015)
REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells
Li Yang et al.
PLOS ONE (2015)
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
Jie Shen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
Min Yang et al.
ONCOLOGY LETTERS (2014)
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
A. Inoue et al.
ANNALS OF ONCOLOGY (2013)
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy
B. Zheng et al.
ANNALS OF ONCOLOGY (2013)
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis
Yu Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial
Marianne C. Nicolson et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
REV3L 3′UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility
S. Zhang et al.
ONCOGENE (2013)
Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells
Aitziber Buque et al.
PLOS ONE (2013)
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Nitzan Gonen et al.
DRUG RESISTANCE UPDATES (2012)
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer
Paolo Ceppi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Luis Paz-Ares
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Ming Li et al.
PLOS ONE (2012)
DNA Polymerase ζ Is a Major Determinant of Resistance to Platinum-Based Chemotherapeutic Agents
Shilpy Sharma et al.
MOLECULAR PHARMACOLOGY (2012)
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines
Dan Zhang et al.
CANCER LETTERS (2011)
Loss of DNA Polymerase zeta Enhances Spontaneous Tumorigenesis
John P. Wittschieben et al.
CANCER RESEARCH (2010)
Molecular Mechanism of Chemoresistance by Astrocyte Elevated Gene-1
Byoung Kwon Yoo et al.
CANCER RESEARCH (2010)
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer
Hiroaki Ozasa et al.
CANCER SCIENCE (2010)
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Jason Doles et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer
Libing Song et al.
JOURNAL OF PATHOLOGY (2009)
Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol ζ
J-M Brondello et al.
ONCOGENE (2008)
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Shrikanta Chattopadhyay et al.
MOLECULAR CANCER THERAPEUTICS (2007)
FMOE-MR: Content-driven multi-resolution MPEG-4 fine grained scalable layered video encoding
S. Chattopadhyay et al.
MULTIMEDIA COMPUTING AND NETWORKING 2007 (2007)
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
Paolo Ceppi et al.
CANCER (2006)
The overexpression of specialized DNA polymerases in cancer
MR Albertella et al.
DNA REPAIR (2005)
Share Paper
